Repotrectinib Gets Priority Review for ROS1-Positive NSCLC
The FDA has accepted for priority review the new drug application for repotrectinib to treat ROS1+ locally advanced or metastatic NSCLC.
Source: cancertherapyadvisor.com
Page 27 - Accessed May News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Accessed May. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Accessed May Today - Breaking & Trending Today
New dietary recommendations, dyslipidemia guidelines and more to be featured at NLA 2023
The National Lipid Association Scientific Sessions will be held today to Sunday and will spotlight statements on nutrition in adults with dyslipidemia, include sessions on the integration of lipid guidelines in clinical practice and more.Healio | Cardiology Today spoke with NLA President Kevin C. Maki, PhD, CLS, FNLA, FTOS, FACN, chief scientist at Midwest Biomedical Research and adjunct
Source: healio.com
Johnson & Johnson : TREMFYA® (guselkumab) Provides Sustained Improvements Across All Minimal Disease Activity Domains for Adults Living with Active Psoriatic Arthritis in Phase 3b Trial
SPRING HOUSE, PENNSYLVANIA, May 31, 2023 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 3b COSMOS clinical trial showing that treatment... | May 31, 2023
Source: marketscreener.com
Jazz Pharmaceuticals Demonstrates Continued Leadership in Sleep Medicine with New Data Presentations at SLEEP 2023
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that seven abstracts featuring new data from across its sleep medicine portfolio will...
Source: prnewswire.com
Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Demonstrates Continued Leadership in Sleep Medicine with New Data Presentations at SLEEP 2023
Seven abstracts emphasize Jazz's commitment to advancing the care and understanding of debilitating sleep disorders such as narcolepsy and idiopathic hypersomnia DUBLIN, May 31, 2023 /PRNewswire/
Source: finanznachrichten.de